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Objectives: To present our experience of video-assisted thoraco-
scopic surgery (VATS) for patients with solitary fibrous tumors of
the pleura (SFTPs) and to discuss the treatment of choice of such
neoplasms.
Methods: Between June 2000 and September 2008, 21 patients with
SFTPs (9 men and 12 women) underwent VATS at our department.
The mean age was 52.5 years (range, 33–76 years).
Results: Surgical excision was performed in all patients. Surgical
excision was performed by VATS in 15 patients (71.4%), by VATS
plus a small thoracotomy (5 cm) in 4 patients (19.0%), and by
posterolateral thoracotomy accompanied by VATS in 2 patients
(9.5%). Mean chest drain duration was 2.3 days (range, 1–4 days),
and the mean hospital stay was 7.2 days (range, 4–15 days). There
were 18 pathologically benign SFTP cases (85.7%) and 3 malignant
SFTP cases (14.3%). There was no operative morbidity or mortality.
No recurrence or metastasis of SFTPs developed during postopera-
tive median follow-up period of 43 months.
Conclusions: Complete resection and close follow-up for years after
operation is recommended for SFTPs. VATS may play an important
role in reducing the size of the thoracotomy incision in the treatment
of SFTPs, which results in less invasive surgery.
Key Words: Solitary fibrous tumors of the pleura, Video-assisted
thoracoscopic surgery, Immunohistochemical analysis.
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Solitary fibrous tumors of the pleura (SFTPs) are rareneoplasms that usually originate from the visceral pleura.
Because its pathologic characteristics was first described by
Klemperer and Rabin1 in 1931, the nomenclature has become
confused, and the disease has also been referred to as a
localized mesothelioma, localized fibrous tumor, fibrous me-
sothelioma, or a pleural fibroma.2 The further development of
electron microscopy and immunohistochemistry has clarified
that the tumor does not originate from the mesothelial layer
but from the submesothelial, noncommitted mesenchymal
layer.3,4 Thus, the various names used for this disease have
become unified, and the disease is now referred to as solitary
or localized fibrous tumors of the pleura. Mesenchyme is
pluripotent tissue and possesses diverse differentiation poten-
tial to bone, cartilage, or blood vessels. Because of this
diversity of the mesenchyme, the pathologic morphology of
SFTP seems variable.5 Recent studies on SFTP have mainly
involved immunologic markers for pathologic diagnosis6,7
and some clinical reports that include postsurgical resection
results and description of its clinical behavior.8–10
Complete surgical resection is the treatment of choice
for SFTP.11 Pedunculate tumors can be safely treated by
wedge resection. For these pedunculate tumors, video-as-
sisted thoracoscopic surgery (VATS) provides a powerful and
useful approach. In addition, some authors have reported the
assistance of thoracoscopy to obtain a more precise view of
the resection margins, even in parietal tumors.12,13 Although
a small thoracotomy can be added to the VATS for the
removal of large tumors, VATS plays an important role in
reducing the size of the thoracotomy incision, which results
in less invasive surgery.14 Initially, we selected a thoraco-
scopic approach for the resection of SFTPs in all cases. Even
with large tumors, if a VATS resection is technically feasible,
it can be carried out. If necessary, we add a small thoracot-
omy incision to remove the tumor safely and completely,
with free surgical margins. The aim of this study was to
present our experience of VATS for 21 consecutive cases
with SFTPs and to discuss the treatment of choice of such
neoplasms.
PATIENTS AND METHODS
Between June 2000 and September 2008, 21 patients
with SFTPs (9 men and 12 women) underwent VATS at our
department. The mean age was 52.5 years (range, 33–76
years). Chest pain (in one patient), dyspnea (in five patients),
cough (in six patients), and hemoptysis (in one patient) were
the symptoms. Fifteen patients were symptom-free. On phys-
ical examination, dullness to percussion and absence of
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breath sounds in the ipsilateral hemithorax were detected in
all patients, and clubbing was present in three patients. None
of the patients presented with a history of hypoglycemia, but
two of them were associated with diabetes mellitus. No
history of exposure to asbestos was recorded in any patient.
Twelve of the patients were current smokers or ex-smokers.
All patients underwent chest roentgenography and computed
tomography (CT) scanning of the chest. A moderate pleural
effusion was associated with six patients (in all the cases, the
main diameter of the tumor was 5 cm). Fiberoptic bron-
choscopy was performed in five patients. In all of them,
extrinsic compression of segmental bronchi was observed,
but no endobronchial lesion was detected. One patient under-
went CT-guided, fine-needle aspiration biopsy; specimen was
not significant by histologic examination. In brief of the
technical aspects of VATS, general anesthesia with selective
lung ventilation was performed with the use of a double-
lumen endotracheal tube. When postoperative mechanical
ventilation was necessary, a standard endotracheal tube was
substituted for the double-lumen tube. Patients were placed in
the lateral decubitus position. Two thoracoports were placed
in the sixth or seventh intercostal space (ICS) on the anterior
axillary line and in the seventh or eighth ICS on the posterior
axillary line; an anterolateral minithoracotomy (2.5–5 cm)
was made in the fourth or fifth ICS. The cautery was used in
the excision SFTPs from the parietal pleura.
We reexamined pathologic slides, and malignant SFTP
was diagnosed when one of following criteria was satisfied:
increasing mitotic activity (4 mitoses per 10 high-power
fields); high cellularity with crowding and overlapping of
nuclei; presence of necrosis; and mild, moderate, or marked
pleomorphism.10 To differentiate the cell origin of resected
tumors, we performed immunostaining for a panel of cell mark-
ers including vimentin, CD34, cytokeratin, desmin, S-100, Ki-
67, and actin.5 Operative mortality was defined as death within
30 days of an operation or during hospitalization. Recent patient
status was determined by using the clinical records of outpatient
clinics or by telephone interview.
RESULTS
Surgical excision was performed in all patients. Surgi-
cal excision was performed by VATS in 15 patients (71.4%),
by VATS plus a small thoracotomy (5 cm) in 4 patients
(19.0%), and by posterolateral thoracotomy accompanied by
VATS in 2 patients (9.5%). Mean chest drain duration was
2.3 days (range, 1–4 days), and the mean hospital stay was
7.2 days (range, 4–15 days). There was no operative mor-
bidity or mortality. At surgery, 14 tumors (66.7%) arising
from the visceral pleura were pedunculate and 7 tumors
(33.3%) from the parietal pleura presented with a broad base
of attachment. All tumors were resected with free surgical
margins. The largest mass excised in our patients was 18.5 cm
17 cm 13.5 cm. The smallest one was 0.5 cm 0.6 cm 4.0
cm. The median size of the tumors resected was 6.5 cm
(range, 4.0–18.5 cm). Pathologic margins of all cases were
confirmed by frozen sectioning free of cancer. On sectioning,
the tumors showed a whorled, fleshy appearance, sometimes
alternating with some myxoid areas. Focal necrosis and
hemorrhagic zones were found in three cases (14.3%), all
relatively large in diameter (5 cm).
Microscopically, all the tumors consisted of spindle-
shaped cells. The tumor cells and intercellular collagen fibers
proliferated without obvious direction or structure, which
corresponded to the so-called “patternless pattern” (Figure
1A). There were 18 pathologically benign SFTP cases (85.7%)
and 3 malignant SFTP cases (14.3%) who were focally
characterized by a mitotic count in excess of 4 mitoses per 10
high-power fields and by cellular pleomorphism. Chest CT
scan of all three histologically malignant SFTP showed the
supply of blood vessels within the tumor and/or liquefaction
necrosis (Figure 1D). Immunohistochemical analysis re-
vealed positivity for CD34 and vimentin in all tumors (Fig-
ures 1B, C) and no expression of cytokeratin, desmin, S-100,
Ki-67, or actin in any of the tumors. No adjuvant therapy was
used. All patients were included in a follow-up program that
included clinical examination and chest roentgenogram after
1, 3, and 6 months postoperatively, and annually thereafter.
The median follow-up time was 43 months (range, 3–96
months). All of the patients have remained well, with no
recurrence or metastasis of the tumors.
DISCUSSION
SFTPs are uncommon, representing less than 5% of all
neoplasms involving the pleura.15 Diagnostic tools, such as
chest radiography, CT scanning, and magnetic resonance
imaging, are helpful but not decisive in establishing the
diagnosis. In most cases, thoracic CT scan shows a well-
circumscribed round tumor with a homogenous density.
However, these findings lack specificity and other imaging
findings are possible. Thus, CT scan cannot differentiate
benign from malignant SFTPs.10,16 Difficulties in differenti-
ating these tumors from others originating from mediastinum
or chest wall are possible. Furthermore, if the lesion is not
homogeneous, the differential diagnosis with a bronchogenic
carcinoma may be also more difficult, especially in the
presence of a smoking history (as in 57.1% of our patients).
Even fine-needle aspiration is often inconclusive, in fact, only
four of nine cases (45%) were identified by CT guided
aspiration biopsy.17,18 Only surgical excision, with subse-
quent immunohistologic examination, can be diagnostic. Im-
munohistochemically positive CD34 staining is decisive in
establishing the diagnosis differentiating SFTPs from me-
sotheliomas, synovial sarcomas, fibrosarcomas, and neuro-
genic tumors. In addition, the bcl-2 essay can confirm the
diagnosis of SFTPs in case of CD34 negativity.19,20 In our
experience, malignant forms of SFTPs accounted for 14.3%
of all cases, whereas it was observed 7% in the experience of
Cardillo et al.,11 30% in the experience of de Perrot et al.,8
36% in the experience of England et al.,21 38% according to
Rena et al.,9 and 60% in the experience of Suter et al.22 This
variability could be probably justified either by the heteroge-
neity in studied populations or by relative subjectivity in the
recognition of some pathology criteria, especially hypercel-
lularity and pleomorphism.
Complete surgical excision with underlying tissue re-
moval lends itself to complete cure and minimizes tumor
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recurrence. For the pedunculate tumors, therefore, VATS is a
useful approach. Even when it is necessary to perform a small
thoracotomy in addition to VATS for the removal of a large
tumor, VATS may play an important role in reducing the size
of the thoracotomy incision, which results in less invasive
surgery. To minimize postoperative morbidity, VATS may be
the most promising surgical approach for the resection of
SFTPs. Six of 60 patients (10.0%) and 22 of 63 patients
(34.9%) with SFTPs successfully underwent VATS in the
experience of Magdeleinat et al.10 and Sung et al.,23 respec-
tively. Takahama et al.14 did the first study to evaluate the
advantage of VATS for patients with SFTPs. In that study,
surgical excision was performed with VATS only in nine
patients, with VATS plus a small thoracotomy in three
patients, and by a posterolateral thoracotomy without VATS
in one patient. The mean chest-drain duration was 1.3 days
(range, 1–3 days), and the mean duration of hospital stay was
8.6 days (range, 3–30 days). With a median of 42-month
follow-up (range, 6–120 months), all patients have remained
well with no recurrence or metastasis. Nomori et al.12 re-
ported that contact metastasis and local recurrence had oc-
curred at the port site, which was used during the VATS
procedure. To avoid contact metastasis and local recurrence
at the port site, we extract the surgical specimen by means of
a retrieval bag. In our series of 21 cases, no recurrence or
metastasis of SFTPs developed during postoperative median
follow-up period of 43 months. However, three cases showed
a mitotic count in excess of 4 mitoses per 10 high-power
fields or cellular pleomorphism, all of which are considered
to indicate potentially malignant SFTPs.
Because of the rarity of these tumors, there is no
systematic assessment of the role of adjuvant therapy in
SFTPs.2,11,24 Anecdotal reports describe long-term survivals
with postoperative radiotherapy in patients with incomplete
resection of the tumor. Responses to ifosfamide and doxoru-
bicin have been reported for recurrent, inoperable SFTP.
Nevertheless, recurrent benign or malignant tumors should be
strongly considered first for repeat surgical resection. After
resection, adjuvant therapy should be considered for recurrent
tumors, particularly the sessile, malignant variety, although
little experience is described in the literature with postoper-
ative treatment.2
In conclusion, complete resection and close follow-up
for years after operation is recommended for SFTPs. VATS
may play an important role in reducing the size of the
thoracotomy incision in the treatment of SFTPs, which results
FIGURE 1. A, The tumor cells and intercellular collagen fibers proliferated without obvious direction or structure, which cor-
responded to the so-called patternless pattern (40); (B) Immunohistochemical analysis revealed positivity for CD34 in all tu-
mor cells (40); (C) Immunohistochemical analysis revealed positivity for vimentin in all tumor cells (40); (D) Three-dimen-
sional reconstruction of enhanced computed tomography (CT) scan (coronal images), we can see the supply of blood vessels
within the tumor (dotted arrow) and liquefaction necrosis (solid line arrow).
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in less invasive surgery. Further studies are required to
identify reliable prognostic factors and multicenter trials to
evaluate the effectiveness of preoperative or postoperative
systemic therapy.
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